Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2007;100:1442-1451
Published online before print April 26, 2007, doi: 10.1161/01.RES.0000268411.49545.9c
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
100/10/1442    most recent
01.RES.0000268411.49545.9cv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yano, M.
Right arrow Articles by Araki, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yano, M.
Right arrow Articles by Araki, E.
Related Collections
Right arrow Cell signalling/signal transduction
Right arrow Growth factors/cytokines
Right arrow Lipid and lipoprotein metabolism
Right arrow Other Vascular biology
Right arrowRelated Article
(Circulation Research. 2007;100:1442.)
© 2007 American Heart Association, Inc.


Molecular Medicine

Statins Activate Peroxisome Proliferator-Activated Receptor {gamma} Through Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase–Dependent Cyclooxygenase-2 Expression in Macrophages

Miyuki Yano*, Takeshi Matsumura*, Takafumi Senokuchi, Norio Ishii, Yusuke Murata, Kayo Taketa, Hiroyuki Motoshima, Tetsuya Taguchi, Kazuhiro Sonoda, Daisuke Kukidome, Yoh Takuwa, Teruo Kawada, Michael Brownlee, Takeshi Nishikawa, Eiichi Araki

From the Department of Metabolic Medicine (M.Y., T.M., T.S., N.I., Y.M., K.T., H.M., T.T., K.S., D.K., T.N., E.A.), Graduate School of Medical Sciences, Kumamoto University, Japan; Department of Physiology (Y.T.), Graduate School of Medicine, Kanazawa University, Japan; Laboratory of Nutrition Chemistry (T.K.), Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Japan; and Department of Medicine, Diabetes Research Center (M.B.), Albert Einstein College of Medicine, Bronx, NY.

Correspondence to Takeshi Matsumura, MD, PhD, Department of Metabolic Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Kumamoto 860-8556, Japan. E-mail takeshim{at}gpo.kumamoto-u.ac.jp

Both statins and peroxisome proliferator-activated receptor (PPAR){gamma} ligands have been reported to protect against the progression of atherosclerosis. In the present study, we investigated the effects of statins on PPAR{gamma} activation in macrophages. Statins increased PPAR{gamma} activity, which was inhibited by mevalonate, farnesylpyrophosphate, or geranylgeranylpyrophosphate. Furthermore, a farnesyl transferase inhibitor and a geranylgeranyl transferase inhibitor mimicked the effects of statins. Statins inhibited the membrane translocations of Ras, RhoA, Rac, and Cdc42, and overexpression of dominant-negative mutants of RhoA (DN-RhoA) and Cdc42 (DN-Cdc42), but not of Ras or Rac, increased PPAR{gamma} activity. Statins induced extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) activation. However, DN-RhoA and DN-Cdc42 activated p38 MAPK, but not ERK1/2. ERK1/2- or p38 MAPK–specific inhibitors abrogated statin-induced PPAR{gamma} activation. Statins induced cyclooxygenase (COX)-2 expression and increased intracellular 15-deoxy-{Delta}12,14-prostaglandin J2 (15d-PGJ2) levels through ERK1/2- and p38 MAPK–dependent pathways, and inhibitors or small interfering RNA of COX-2 inhibited statin-induced PPAR{gamma} activation. Statins also activate PPAR{alpha} via COX-2–dependent increases in 15d-PGJ2 levels. We further demonstrated that statins inhibited lipopolysaccharide-induced tumor necrosis factor {alpha} or monocyte chemoattractant protein-1 mRNA expression, and these effects by statins were abrogated by the PPAR{gamma} antagonist T0070907 or by small interfering RNA of PPAR{gamma} or PPAR{alpha}. Statins also induced ATP-binding cassette protein A1 or CD36 mRNA expression, and these effects were suppressed by small interfering RNAs of PPAR{gamma} or PPAR{alpha}. In conclusion, statins induce COX-2–dependent increase in 15d-PGJ2 level through a RhoA- and Cdc42-dependent p38 MAPK pathway and a RhoA- and Cdc42-independent ERK1/2 pathway, thereby activating PPAR{gamma}. Statins also activate PPAR{alpha} via COX-2–dependent pathway. These effects of statins may explain their antiatherogenic actions.


Key Words: cyclooxygenase • MAPK • macrophages • PPAR • statins


Related Article:

Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of Statins
Réjane Paumelle and Bart Staels
Circ. Res. 2007 100: 1394-1395. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. Amoruso, C. Bardelli, L. G. Fresu, A. Palma, M. Vidali, V. Ferrero, F. Ribichini, C. Vassanelli, and S. Brunelleschi
Enhanced Peroxisome Proliferator-Activated Receptor-{gamma} Expression in Monocyte/Macrophages from Coronary Artery Disease Patients and Possible Gender Differences
J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 531 - 538.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Bujold, D. Rhainds, C. Jossart, M. Febbraio, S. Marleau, and H. Ong
CD36-mediated cholesterol efflux is associated with PPAR{gamma} activation via a MAPK-dependent COX-2 pathway in macrophages
Cardiovasc Res, August 1, 2009; 83(3): 457 - 464.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. P. Ramji
Growth hormone-releasing peptides, CD36, and stimulation of cholesterol efflux: cyclooxygenase-2 is the link
Cardiovasc Res, August 1, 2009; 83(3): 419 - 420.
[Full Text] [PDF]


Home page
EndocrinologyHome page
C. Nacci, M. Tarquinio, L. De Benedictis, A. Mauro, A. Zigrino, M. R. Carratu, M. J. Quon, and M. Montagnani
Endothelial Dysfunction in Mice with Streptozotocin-induced Type 1 Diabetes Is Opposed by Compensatory Overexpression of Cyclooxygenase-2 in the Vasculature
Endocrinology, February 1, 2009; 150(2): 849 - 861.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Zampetaki and Q. Xu
Vascular Remodeling in Diabetes: Don't Leave Without Your STAT5
Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 10 - 11.
[Full Text] [PDF]


Home page
Mol Cancer ResHome page
S. Han, X. Sun, J. D. Ritzenthaler, and J. Roman
Fish Oil Inhibits Human Lung Carcinoma Cell Growth by Suppressing Integrin-Linked Kinase
Mol. Cancer Res., January 1, 2009; 7(1): 108 - 117.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
X. Sun, J. D. Ritzenthaler, Y. Zheng, J. Roman, and S. Han
Rosiglitazone inhibits {alpha}4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor {gamma}-independent signals
Mol. Cancer Ther., January 1, 2009; 8(1): 110 - 118.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
V. Paul, H. H. D. Meyer, K. Leidl, S. Soumian, and C. Albrecht
A novel enzyme immunoassay specific for ABCA1 protein quantification in human tissues and cells
J. Lipid Res., October 1, 2008; 49(10): 2259 - 2267.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
K. P. Sundararaj, D. J. Samuvel, Y. Li, A. Nareika, E. H. Slate, J. J. Sanders, M. F. Lopes-Virella, and Y. Huang
Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation
J. Leukoc. Biol., October 1, 2008; 84(4): 1120 - 1129.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
X. R. Chen, V. C. Besson, T. Beziaud, M. Plotkine, and C. Marchand-Leroux
Combination Therapy with Fenofibrate, a Peroxisome Proliferator-Activated Receptor {alpha} Agonist, and Simvastatin, a 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitor, on Experimental Traumatic Brain Injury
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 966 - 974.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Taketa, T. Matsumura, M. Yano, N. Ishii, T. Senokuchi, H. Motoshima, Y. Murata, S. Kim-Mitsuyama, T. Kawada, H. Itabe, et al.
Oxidized Low Density Lipoprotein Activates Peroxisome Proliferator-activated Receptor-{alpha} (PPAR{alpha}) and PPAR{gamma} through MAPK-dependent COX-2 Expression in Macrophages
J. Biol. Chem., April 11, 2008; 283(15): 9852 - 9862.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Kourimate, C. Le May, C. Langhi, A. L. Jarnoux, K. Ouguerram, Y. Zair, P. Nguyen, M. Krempf, B. Cariou, and P. Costet
Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9
J. Biol. Chem., April 11, 2008; 283(15): 9666 - 9673.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
E. Erdmann
Review: Statin plus thiazolidinedione use in patients with diabetes at high cardiovascular risk
The British Journal of Diabetes & Vascular Disease, September 1, 2007; 7(5): 211 - 216.
[Abstract] [PDF]


Home page
Circ. Res.Home page
R. Paumelle and B. Staels
Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of Statins
Circ. Res., May 25, 2007; 100(10): 1394 - 1395.
[Full Text] [PDF]